My Personal CFO LLC Sells 141 Shares of Johnson & Johnson (NYSE:JNJ)

My Personal CFO LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 3.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,371 shares of the company’s stock after selling 141 shares during the quarter. My Personal CFO LLC’s holdings in Johnson & Johnson were worth $639,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of JNJ. Tennessee Valley Asset Management Partners raised its holdings in shares of Johnson & Johnson by 3.1% in the 4th quarter. Tennessee Valley Asset Management Partners now owns 2,666 shares of the company’s stock valued at $418,000 after purchasing an additional 80 shares in the last quarter. GUNN & Co INVESTMENT MANAGEMENT INC. raised its stake in shares of Johnson & Johnson by 1,194.9% during the 4th quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock worth $37,190,000 after acquiring an additional 218,949 shares in the last quarter. Duality Advisers LP bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $3,529,000. Telemus Capital LLC raised its stake in shares of Johnson & Johnson by 0.5% during the 4th quarter. Telemus Capital LLC now owns 20,157 shares of the company’s stock worth $3,159,000 after acquiring an additional 104 shares in the last quarter. Finally, Diversified LLC raised its stake in shares of Johnson & Johnson by 11.8% during the 4th quarter. Diversified LLC now owns 6,469 shares of the company’s stock worth $1,014,000 after acquiring an additional 682 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. TD Securities reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, August 5th. The Goldman Sachs Group lowered their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 30th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $162.95 on Wednesday. The company’s 50-day moving average price is $154.30 and its 200-day moving average price is $153.26. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company has a market cap of $392.17 billion, a P/E ratio of 10.16, a P/E/G ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $166.21.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period last year, the firm posted $2.80 earnings per share. On average, sell-side analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.